Efficacy and Safety of Mirabegron in Patients with Overactive Bladder and Cardiovascular Comorbidities: A Post Hoc Analysis of Randomised Trials

No significant differences in mirabegron efficacy were noted between groups with OAB with and without CRC. Low prevalence of cardiac TEAEs was noted, which indicates that mirabegron was well tolerated in both groups.